Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study

Bone Marrow Transplantation volume 51, pages 1524–1526 (2016)Cite this article

Subjects

Different studies have attempted to identify the best strategy to prevent GvHD1, 2, 3, 4, 5, 6, 7 without hampering GvL. We previously compared the combination of sirolimus (SRL) plus tacrolimus (TKR) with Cyclosporine and mofetil mycophenolate in the setting of unrelated donor (UD) reduced intensity conditioning (RIC),3 and found significantly better outcomes for SRL/TKR in terms of chronic GvHD (55 vs 88%), non-relapse mortality (NRM) (18 vs 38% at 2 years) and overall survival (OS) (72 vs 44%). With this background the use of SRL/TKR has been widespread for alloRIC, regardless of donor type.

We report a total of 122 patients who underwent alloRIC from October 2008 to June 2013 in 6 Spanish centers, with SRL/TKR as GvHD prophylaxis for alloRIC. Two RIC regimens were used, as previously detailed:3, 4 fludarabine plus melphalan or busulfan for lymphoid or myeloid malignancies, respectively. Data on doses and schedule of SRL/TKR have also been described.3

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Nakamura R, Forman SJ . Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GvHD prophylaxis. Expert Rev Hematol 2014; 7: 407–421.

    Article  CAS  Google Scholar 

  2. Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S et al. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Leuk Lymphoma 2015; 56: 663–670.

    Article  CAS  Google Scholar 

  3. Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D et al. The combination of Sirolimus plus Tacrolimus improves outcome after reduced-intensity conditioning unrelated donor hematopoietic stem cell transplantation compared with Cyclosporine plus Mycofenolate. Haematologica 2013; 98: 526–532.

    Article  Google Scholar 

  4. Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, Cámara R et al. Reduced intensity conditioning allogeneic transplantation from unrelated donors: evaluation of Mycophenolate Mofetil plus Cyclosporin A as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2008; 14: 664–671.

    Article  Google Scholar 

  5. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A et al. A phase II pilot study of tacrolimus/sirolimus GvHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010; 115: 1098–1105.

    Article  CAS  Google Scholar 

  6. Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after nonmyeloablative unrelated donor transplantation. Haematologica 2014; 99: 1624–1631.

    Article  CAS  Google Scholar 

  7. Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D et al. Tacrolimus/sirolimus versus tacrolimus/ methotrexate as GvHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood 2014; 124: 1372–1377.

    Article  CAS  Google Scholar 

  8. Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012; 97: 1882–1889.

    Article  CAS  Google Scholar 

  9. Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016; 173: 96–104.

    Article  CAS  Google Scholar 

  10. Solomon S, Sanacore M, Zhang X, Brown S, Holland K, Morris LE et al. Calcineurin Inhibitor (CNI)-Free GvHD Prophylaxis with Post-Transplant Cyclophosphamide (Cy) and Brief-Course Sirolimus Following Reduced Intensity Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant 2014; 20: 1828–1834.

    Article  CAS  Google Scholar 

  11. Caballero-Velázquez T, Sánchez-Abarca LI, Gutierrez-Cosio S, Blanco B, Calderon C, Herrero C et al. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. Haematologica 2012; 97: 1329–1337.

    Article  Google Scholar 

  12. Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A et al. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1734–1744.

    Article  CAS  Google Scholar 

  13. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551–557.

    Article  CAS  Google Scholar 

  14. Corzo-León DE, Satlin MJ, Soave R, Shore TB, Schuetz AN, Jacobs SE et al. Epidemiology and outcomes of invasive fungal infections in allogeneichaematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses 2015; 58: 325–336.

    Article  Google Scholar 

  15. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26: 5767–5774.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work has been partially supported by the RTICC RD12/0036/0052, RTICC RD12/0036/0071, AGAUR 2014 SGR 1281 and PI11/02366.

Author information

Authors and Affiliations

  1. Hospital Universitario Virgen del Rocío/Virgen Macarena, Instituto de Biomedicina de Sevilla (IBIS), Universidad de Sevilla, Sevilla, Spain

    R Parody, F J Marquez-Malaver & J A Pérez-Simon

  2. Hospital Universitario de Salamanca, Salamanca, Spain

    L López-Corral, O Lopez-Godino, D Caballero, L Vazquez & F Sanchez-Guijo

  3. Hospital,

    C Martinez

  4. Clinic de Barcelona, Barcelona, Spain

    C Martinez

  5. Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras,

    R Martino, I García-Cadenas & A Esquirol

  6. Institute, Universidad Autónoma de Barcelona, Barcelona, Spain

    R Martino, I García-Cadenas & A Esquirol

  7. Hospital Clínico de Valencia, Valencia, Spain

    C Solano, J L Piñana & J C H Boluda

  8. Hospital Vall d’Hebron, Barcelona, Spain

    P Barba

Authors
  1. R Parody
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L López-Corral
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Lopez-Godino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Solano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Barba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Caballero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I García-Cadenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J L Piñana
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F J Marquez-Malaver
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L Vazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Esquirol
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J C H Boluda
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. F Sanchez-Guijo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J A Pérez-Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the GETH (Grupo Español de TrasplanteHematopoyético)

Corresponding author

Correspondence to J A Pérez-Simon.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parody, R., López-Corral, L., Lopez-Godino, O. et al. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. Bone Marrow Transplant 51, 1524–1526 (2016). https://doi.org/10.1038/bmt.2016.163

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.163

This article is cited by

Search

Advanced search

Quick links